Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata

BACKGROUND. Alopecia areata (AA) is a common autoimmune disease with a lifetime risk of 1.7%; there are no FDA-approved treatments for AA. We previously identified a dominant IFN-γ transcriptional signature in cytotoxic T lymphocytes (CTLs) in human and mouse AA skin and showed that treatment with J...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:JCI Insight
Huvudupphovsmän: Mackay-Wiggan, Julian, Jabbari, Ali, Nguyen, Nhan, Cerise, Jane E., Clark, Charlotte, Ulerio, Grace, Furniss, Megan, Vaughan, Roger, Christiano, Angela M., Clynes, Raphael
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Society for Clinical Investigation 2016
Ämnen:
Clinical Medicine
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5033756/
https://ncbi.nlm.nih.gov/pubmed/27699253
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.89790
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk